Presented by:

Alex Shneider, Ph.D., Founder and CEOGene Froelich, CFO/COO

Jeffery East, EVP of Business Development

WWW.CURELAB.COM

+1-609-841-1201

+7-905-570-3725

2

3

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Act of1995. In accordance with the safe harbor provisions of the Private SecuritiesLitigation reform Act of 1995, the Company notes that statements in this web site,and elsewhere, that look forward in time, which include everything other thanhistorical information, involve risks and uncertainties that may affect theCompany's actual results of operations. The following important factorscould cause actual results to differ materially from those set forth inthe forward-looking statements: project financing; new scientific findings; ourproducts may not be accepted by the market; and we may have difficulty in hiringand retaining key personnel.

Cure Lab Oncology Mission

To overcome the worldwide problem

of cancer by developing and utilizing

novel anti-cancer vaccines and

oncolytic viruses

4

5

Cure Lab’s Executive Summary

Competitive advantage Novel oncolytic virus and product pipeline Novel anticancer immunostimulant and the product pipeline Novel technologies to increase vaccine and oncolytic virus efficiency Anti-cancer vaccine and oncolytic virus may eventually merge into a single

productAnticipated Investment and Results by 2015 $10 M of investment Finalize clinical testing in the Former USSR Licensing to big pharma for >$1BValuation of the Company by mid-2014 >1B Multiple of 100X

6

Cancer in Russia

300,000 people die each year due to cancer

2,500,000 people are diagnosed with cancer

From 1997 to 2007 the number of cancer patients has increased 13%

9

Oncolytic Viruses

Oncolytic Viruses – viruses that selectively destroy tumors without impacting normal tissue

Benefits

Selectivity

Effective tumor removal

Limited or no side-effects

Cost-efficiency For some cancers, oncolytic viruses are the only life-saving option

China has approved world's first oncolytic virus therapy for cancer treatment

http://www.med.emory.edu/index5.cfm

PBS HIF-Ad-IL4 PBS HIF-Ad-IL4

B. Day 35

1

implanttumor i.c.

8

image

35

imageVirus2 x 108 IFU

A. Day 8

HIF-Ad-IL4 has potent anti-tumor activity againstorthotopic human brain tumor in athymic nu/nu mice model

survival

C. luciferase expression

PBS HIF-Ad-IL40

15

30

45

60

75

90

Fo

ld I

nc

reas

e(D

ay

35/D

ay 8

)

p=0.001

D. Survival Curve

athymic nu/nu mice

0 50 100 150 2000

25

50

75

100

PBS (n=10)(median=55 days)

HIF-Ad-IL4 (n=10)(median=160 days)

p=.0001Days Post tumor implant

Per

cen

t s

urv

ival

D.E. Post et al., unpublished data

12

Kidney Caner in Russia

17,600 diagnosed cases in 2008

47% increase compared with 2000

Significant increase in disease is reported for patients starting 35-39 years old and max at 65-69

High level of HIF (hypoxia induced factor), which activated our oncolytic virus. This makes the project of relatively low risk.

13

Prostate Cancer in Russia

1 out of 7 men over 50 suffer prostate cancer

>15% lethality rate

Current treatment methods lead to impotency

14

Breast Cancer in Russia

50,000 women per year suffer breast cancer

41% of the cases are diagnosed at late stages

20,000 women die each year

15

Cancer Vaccines

Induce tumor-specific protective immune response

Anti-tumor therapeutic agents

Preventive means to preclude tumor relapse after surgical removal

Future use: preventive vaccination for high risk groups (genetic markers, family history, occupational hazard)

a; T5 tumors in control treated (pcDNA3.1) rats

b&c; T5 tumors after pCL DNA therapy

b

ca

nt

nt; necrotic tumor

17

Intellectual Property

Issued US, Australian and European patents for the product (both umbrella and application coverage)

Russia patent application submitted with Skolkovo’s assistance

A pipeline of the follow-up patent applications to be submitted for product modifications

Cure Lab’s technological and clinical know-how developed over the years

18

US Market Size for Cancer Drugs

$40.3B in 1990

$216B in 2006

19

Market Comparables (Yervoy)

Antibody blocking CTLA-4 inactivating lymphocytes

CTLA-4 discovered in UC Berkley in the mid 1990th. No pharm company was interested in “too new” idea.

1998 Berkley licenses it to NeXstar Pharmaceuticals

1999 NeXstar Pharmaceuticals sublicenses it to Medarex for $8.5M

2009 Medarex acquired by Bristol-Myers for $2.4B based on its anti-CTLA-4 antibody product (no clinical trial results yet)

20

Market Comparables Bevacizumab (Avastin)

Monoclonal antibody blocking growth of blood vessels in

tumors (Genentech ).

Used for colon, breast and lung cancer.

$4,000-9,000/moth/patient

Insurance paid $100,000/year per patient

2007 sales:

$2.3B USA

$3.5B worldwide

Prolongs life for 4.7 month in average

21

Competition

Developers of chemical anti-cancer drugs Developers of biological anti-cancer drugs Anti-cancer vaccines Other companies working on oncolytic viruses (Israel, Japan, USA, EU)

“Cancer” is a composite name for multiple diseases (different mechanisms withsimilar clinical manifestations). Thus, there are several applications for ourapproach with no real competition but with compelling market need.

Major pharmaceutical companies run out of patent protection on their anti-cancerdrugs. Thus, demand for new anti-cancer medicine greatly exceeds supply.

Different treatments are typically used in combination, thus they do notcompete but complement each other

22

Timeline and Operational Capital Requirements

  Task and Timeline in Months Appr Cost ($ M) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2 3 3 3 4 3 5 3 6

1Licensing from Emory University 0.125                                                                        2Permission To Import Virus to Russia

                                                                         3Specific List of Documents Required to Get Permission for

Clinical Trails in Russia                                                                        4Manufacture Virus for Pre-clinical Trails

0.1                                                                      5Pre-clinical Toxicity Tests 0.1                                                                        6Develop and Approve Clinical Trail Protocol(s)

0.25                                                                        7Obtain Permission for Clinical Trials                                                                        8Manufacture Virus for Clinical Trials 0.375                                                                        9 Import the Virus for Clinical Trials                                                                          

10Preliminary Clinical Trials (10 patients) 0.4                                                                        

11Clinical Trails 0.8                                                                        12Prepare a Report for UA Pharm Center and FDA

0.35                                                                        13Permit for Clinical Use in UA                                                                          14Organize Profitable Clinical Use in UA                                                                          15Continue R&D as 2-5 1                                                                        

Management & Administrative 0.5                                                                         Miscellaneous 0.5                                                                         TOTAL ($M) $ 4.5                                                                        

23

Combining The Best Of Both Worlds

It is the most feasible to develop future models of the product in the US in active collaboration with institutions in EU and Former USSR

It is the most feasible to conduct pre-clinical and clinical testing of the existing product in the Former USSR

Cure Lab has developed an international network allowing to conduct each part of the project in the country it is the most feasible, minimizing expanses and need for capital while maximizing results

Collaborations

USA:Harvard, Emory University, Boston University, Northeastern University, University of Arkansas, UCSD

Europe:Technical University of Munich, University of Camerino (Italy)

Former USSR:Ivanovsky Institute of Virology, Institute of Viral Preparations, Institute of Gene Biology , Institute of Influenza and other Viral Desiases, Kavetsky Institute of Oncology

24

25

Scientific Advisory Board

Prof. Aaron Ciechanover – Nobel Prize Laureate in Chemistry, 2004. Technion, Haifa, Director of Cancer Control Center, Israel.

Barry Straube, M.D., Senior Medical Advisor, Cure Lab; Immediate Past Chief Medical Officer, Centers for Medicare and Medicaid Services.

Kim Lewis, Ph.D., Professor of Biology, Northeastern University Michael Sherman, Ph.D., Professor of Biochemistry, Boston University School of

Medicine Stuart Calderwood, Ph.D., Associate Professor, Beth Israel Deaconess Medical

Center, Harvard Medical School. Herbert T. Cohen, M.D., Professor of Medicine, Boston University School of

Medicine Mikhail Blagosklonny, M.D., Ph.D., Member/Professor, Roswell Park Cancer

Institute, Editor-in-chief of journals Cell Cycle and Aging Valeria Povolotskaya, Ph.D., Ex-Director of International Licensing Department of

La Roche

26

Scientific Advisory Board, Russia Prof. Anatoly Tsib, Director of Medical Radiological Research Center of RAMS, Active

member of Russian National Academy of Medical Science. Prof. Valeriy Charushin, Deputy of Russian Federation State Duma, Director of Institute of

Organic Synthesis named after I.Ya. Postovsky (http://www.ios.uran.ru/), Chairman of Board of Ural Branch of Russian Academy of Sciences, member of the board of Russian Academy of Sciences, International Society of Heterocyclic Chemistry and International Society for Antiviral Research, International Union of Pure and Applied Chemistry (IUPAC), American Chemical Society, State Duma Committee on Science and High Technology.

Prof. Sergey Kolesnikov, Deputy of Russian Federation State Duma, Chairman of the Board of East-Siberian Scientific Center, Siberian Division of Russian Academy of Medical Sciences, Deputy-Chairman of Committee for Health Care, Distinguished Scientist of Russian Federation, Active member of Russian National Academy of Medical Science.

Prof. Oleg Kiselev, Director of Research Institute of Influenza of Ministry of Health and Social Development of Russian Federation (Saint Petersburg) (http://www.influenza.spb.ru/), member of WHO, Active member of Russian National Academy of Medical Science.

Prof. Nikolay Kaverin, Chief of Applied Virology Laboratory of Ivanovsky Institute of Virology (Moscow), Active member of Russian National Academy of Medical Science.

Management Profiles, USA

Alex Shneider, Ph.D. – Founder and CEO20 years of experience in fundamental and applied bio-medical

research.Section editor of International Review of ImmunologySenior Research Fellow at the Center for History and Philosophy

of Science, Boston UniversityMember of the Board of Trustees of St. Petersburg Institute of

TechnologyAuthor of the best selling book on business analysis in Eastern

Europe.Ph.D. in life science form Roskilder University, Denmark.

27

Management Profiles, USA

Eugene L. “Gene” Froelich, CPA – CFO/COO

Over 30 years of successful business experience

Ex- CEO MCA Records Group

Ex-CFO and EVP of Maxicare Health Plans Inc

Ex-COO and CFO at Wizshop.com

28

Management Profiles, USA

Victor Shifrin, Ph.D., Director of R&DOver 20 years of experience in academia and biotech industry.Formerly Director of Pharmacology at Surface Logix. Worked in

various capacities at Scriptgen (Anadys) and Eisai Research Institute.

Led discovery biology at CombinatoRx, where he studied the combinatorial effects of the approved drugs.

Ph.D. in Cell and Molecular Biology from Harvard University. Postdoctoral training at the Harvard-affiliated Dana Farber Cancer Institute, and Brigham and Women’s Hospital, Harvard Medical School.

29

Management Profiles, USA

Jeff East - Executive Vice President, Strategy/Business Development

25 years of executive level experience across the healthcare industyr.

Former CEO of sister company to New England Journal of Medicine, Masspro.

Former leader of $2 billion hospital medical device and pharmaceutical distribution company

Former senior executive at Massachusetts Department of Public Health

Various health care company board officer and director experience.

30

THANK YOU!